Skip to content

Supplementary data for 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'.

Dataset

  • Dr Marianna Cerasuolo (Creator)
  • Federica Maccarinelli (Creator)
  • Daniela Coltrini (Creator)
  • Ali Mokhtar (Creator)
  • Viviana Marolda (Creator)
  • Gaia Cristina Ghedini (Creator)
  • Sara Rezzola (Creator)
  • Arianna Giacomini (Creator)
  • Luca Triggiani (Creator)
  • Magdalena Kostrzewa (Creator)
  • Roberta Verde (Creator)
  • Debora Paris (Creator)
  • Dominique Melck (Creator)
  • Marco Presta (Creator)
  • Alessia Ligresti (Creator)
  • Roberto Ronca (Creator)

Description

This copy of the Supplementary Material is subject to the same embargo as the post-print and will be available here from 06/02/21.

Content:
Model parameterization
Vehicle and enzalutamide:
-In vitro experiments
Figures SMM1 & SMM2
-In vivo experiments (under skin)
Figures SMM3 & SMM4

Mathematical model for combo therapies: enzalutamide-everolimus or
enzalutamide-cabazitaxel
Everolimus:
-From in vitro experiments
Figures SMM5 & SMM6
-In vivo experiments (under skin)
Figure SMM7

Cabazitaxel:
-In vitro experiments
Figures SMM8 & SMM9
-In vivo experiments (under skin)
Figure SMM10

Sensitivity Analysis
Date made available6 Feb 2020
PublisherUniversity of Portsmouth

Documents

DOI

Related information

Outputs

Relations

ID: 22703508